Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

794 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, et al. Zittoun RA, et al. Among authors: mandelli f. N Engl J Med. 1995 Jan 26;332(4):217-23. doi: 10.1056/NEJM199501263320403. N Engl J Med. 1995. PMID: 7808487 Free article. Clinical Trial.
Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML8 A). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
Zittoun R, Mandelli F, Willemze R, de Witte T, Tura S, Ferrini PR, Stryckmans P, Gattringer C, Petti MC, Solbu G, et al. Zittoun R, et al. Among authors: mandelli f. Leukemia. 1992;6 Suppl 2:114-5. Leukemia. 1992. PMID: 1578909 Clinical Trial. No abstract available.
Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
Zittoun R, Liso V, Mandelli F, Rotoli B, de Witte T, Gattringer C, Resegotti L, Caronia F, Leoni P, Petti MC, et al. Zittoun R, et al. Among authors: mandelli f. Leukemia. 1992;6 Suppl 2:76-7. Leukemia. 1992. PMID: 1578949 Clinical Trial. No abstract available.
[Comparison between intensive consolidation by bone marrow autograft or by chemotherapy of acute myeloblastic leukemias in 1st complete remission: AML8A protocol of the Leukemia Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC)].
Zittoun R, Rio B, Delmer A, Vekhof A, Mandelli F, Willemze R, de Witte T, Tura S, Ferrini PR, Stryckmans P, et al. Zittoun R, et al. Among authors: mandelli f. Nouv Rev Fr Hematol (1978). 1993 Feb;35(1):15-6. Nouv Rev Fr Hematol (1978). 1993. PMID: 8511034 Clinical Trial. French. No abstract available.
Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P, Hayat M, Peetermans M, Cadiou M, Solbu G, Petti MC, Willemze R. Zittoun R, et al. Among authors: mandelli f. J Clin Oncol. 1996 Jul;14(7):2150-9. doi: 10.1200/JCO.1996.14.7.2150. J Clin Oncol. 1996. PMID: 8683249 Free article. Clinical Trial.
Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups.
Keating S, Suciu S, de Witte T, Mandelli F, Willemze R, Resegotti L, Broccia G, Thaler J, Labar B, Damasio E, Bizzi B, Rotoli B, Vekhoff A, Muus P, Petti MC, Dardenne M, Solbu G, Vegna ML, Zittoun RA. Keating S, et al. Among authors: mandelli f. Bone Marrow Transplant. 1996 Jun;17(6):993-1001. Bone Marrow Transplant. 1996. PMID: 8807105 Clinical Trial.
Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial.
Zittoun R, Suciu S, Watson M, Solbu G, Muus P, Mandelli F, Stryckmans P, Peetermans M, Thaler J, Resegotti L, Dardenne M, Willemze R. Zittoun R, et al. Among authors: mandelli f. Bone Marrow Transplant. 1997 Aug;20(4):307-15. doi: 10.1038/sj.bmt.1700888. Bone Marrow Transplant. 1997. PMID: 9285546
Centre effect on treatment outcome for patients with untreated acute myelogenous leukaemia? An analysis of the AML 8A Study of the Leukemia Cooperative Group of the EORTC and GIMEMA. European Organization for Research and Treatment of Cancer (EORTC) Leukemia Cooperative Group and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA).
Keating S, de Witte T, Suciu S, Mandelli F, Damasio E, Willemze R, Morra E, Amadori S, Dardenne M, Vegna ML, Zittoun RA. Keating S, et al. Among authors: mandelli f. Eur J Cancer. 1999 Oct;35(10):1440-7. doi: 10.1016/s0959-8049(99)00148-3. Eur J Cancer. 1999. PMID: 10673975 Clinical Trial.
794 results